Enterococcus is among the top causes of bloodstream infection, infective endocarditis, intra-abdominal sepsis and surgical-site infection. Colonization with vancomycin-resistant Enterococcus (VRE) is associated with antibiotic use, residence in a long-term care facility, renal disease, malignant disease, organ transplant, critical illness, immunocompromise, catheter use and HIV infection. Few antibiotic agents are effective against VRE, and they are not often used in initial empiric treatment regimens. Among patients with sterile-site infections caused by Enterococcus, vancomycin resistance has been associated with higher mortality. A recent study showed that a delay of more than 2 days in receiving effective therapy for VRE infection was associated with a 3-fold increase in 30-day mortality.

The timely identification of antibiotic resistance is challenging. Traditionally, Gram staining results are available early, whereas identification of species has required 2–3 days and determination of susceptibilities longer still. New, rapid diagnostic tools allow for species identification up to 30 hours earlier, which has increased the importance of species-based empiric therapy. As a result, ways are needed to predict the interim likelihood of vancomycin resistance in Enterococcus isolates. The use of swab screening for VRE is attractive because such screening is frequently performed upon admission to hospital. In cases of infection with methicillin-resistant Staphylococcus aureus, results obtained with screening swabs have had high specificity for predicting vancomycin resistance. However, this study aimed to determine whether prior VRE screening swab results represent a useful tool for predicting vancomycin resistance in sterile-site Enterococcus infections. Patients with a positive result for VRE screening swab and Enterococcus identified by culture of sterile-site samples should receive empiric treatment with linezolid or daptomycin until sensitivity results are available.

Abstract

Background: Swab screening for vancomycin-resistant Enterococcus (VRE) is used to identify VRE carriers and thus prevent transmission of this organism. We tested whether screening results could have unintended benefits in predicting the vancomycin susceptibility of subsequent Enterococcus infections experienced by these patients.

Methods: We conducted a retrospective cohort study of all patients admitted to a large tertiary care hospital between 2010 and 2015 who underwent swab screening for VRE before experiencing an Enterococcus sterile-site infection. We derived test characteristics using the screening result as the test variable predicting the presence or absence of vancomycin resistance in the sterile-site Enterococcus species.

Results: Culture results for sterile-site samples were positive for Enterococcus for 619 patients during the study period. Of these, 488 (79%) had previously undergone VRE screening. A total of 19 (4%) of the 488 screening results were positive for VRE, and 10 (2%) of the sterile-site Enterococcus isolates were resistant to vancomycin. The overall specificity of VRE swabs was 97% (95% confidence interval [CI] 96%–99%), sensitivity was 70% (95% CI 35%–93%), the positive likelihood ratio was 28 (95% CI 14–56), and the negative likelihood ratio was 0.31 (95% CI 0.12–0.79). The post-test probability of vancomycin resistance in a sterile-site culture, given a positive result with VRE screening swab, was 37% using study data and 83% using published aggregate prevalence data for VRE in the United States.

Interpretation: Prior VRE screening swab results represent a useful tool for predicting vancomycin resistance in sterile-site Enterococcus infections. Patients with a positive result for VRE screening swab and Enterococcus identified by culture of sterile-site samples should receive empiric treatment with linezolid or daptomycin until sensitivity results are available.

Competing interests: None declared.

This article has been peer reviewed.

Correspondence to: Nick Daneman, nick.daneman@sunnybrook.ca

CMAJ Open 2017. DOI:10.9778/cmajo.20170034
methicillin resistance in subsequent *S. aureus* infections.\textsuperscript{14} Previous studies have evaluated the predictive value of VRE screening swabs in forecasting the prevalence of VRE among all causes of bacterial infection.\textsuperscript{15–19}

In this study, we sought to investigate the utility of results obtained with VRE screening swabs in predicting vancomycin resistance among subsequent sterile-site infections with *Enterococcus*. We hypothesized that among patients with sterile-site *Enterococcus* infections, prior positive results with VRE screening swabs would reliably predict vancomycin resistance, but prior negative results would not reliably rule out vancomycin resistance.

**Methods**

**Design and patient selection**

We performed a retrospective cohort study involving all patients at Sunnybrook Health Sciences Centre, a large tertiary care centre in Toronto, Ontario, who had a sterile-site isolate of *Enterococcus* sp. and prior swab screening for VRE between Apr. 1, 2010, and Dec. 31, 2015. We defined sterile-site isolates as isolates from blood, tissue biopsy specimens and cerebrospinal, pleural, peritoneal or synovial fluid. We included patients who were older than 1 year and had samples taken for culture as outpatients, in the emergency department or during hospital admission (excluding long-term care wards). Each patient was included in the study only once, with the most recent *Enterococcus* isolate and the most recent VRE screening result being used for the study. We excluded patients whose VRE screening was performed after the sample yielding a sterile-site isolate was obtained.

**Data sources**

We derived data from the Stewardship Program Integrated Resource Information Technology database, which is securely and confidentially autopopulated with pharmacy and microbiology data, as well as demographic characteristics, for Sunnybrook patients (inception April 2010).\textsuperscript{20}

**VRE screening protocols and methods**

Screening for VRE, via rectal swabbing, was performed on the first day of admission under the following circumstances: known previous colonization, infection or contact with a resistant organism; previous receipt of health care in a high-risk area outside of Canada; admission to a health care facility within the preceding year; receipt of home health care or hemodialysis; residence in a shelter or other high-risk setting; or inability to answer screening questions. Surveillance swabs were also obtained during transfer to a critical care unit or in the context of an outbreak.

Swabs used for rectal screening were placed in Amies agar gel transport medium with charcoal (Copan Italia) and were cultured on chromogenic media to screen for vancomycin-resistant *Enterococcus faecium* (purple colonies) and vancomycin-resistant *Enterococcus faecalis* (> 10 blue colonies) (Brilliance VRE Agar, Oxoid). Incubation took place at 37°C for 22–24 hours in the dark. Vancomycin resistance was confirmed by sampling the cultures, instilling the samples in Triton X-100 lysis buffer and performing polymerase chain reaction (PCR) for the *vanA* and *vanB* genes (primers developed internally). An intermediate saline dilution method was used for presumed vancomycin-resistant *E. faecalis* colonies. Screening results were deemed positive if both culture and PCR results were positive and were otherwise deemed negative.

When clinically indicated, *Enterococcus* was cultured and identified from sterile-site specimens according to routine practices for the site of origin. Possible *Enterococcus* was identified by the presence of colonies of gram-positive cocci in pairs and chains in appropriate culture media. Species identification was confirmed using Vitek automated biochemical detection (April 2010–August 2014) or the Vitek MS system (August 2014–December 2015) (bioMérieux). Susceptibility testing was performed using the Vitek automated biochemical system (bioMérieux).

**Covariables**

We extracted the following covariables from the database: age, sex, ward, service category, sterile site, *Enterococcus* species, and time between swab screening and sterile-site sampling for culture. We used these data to inform the baseline characteristics of screened patients.

**Statistical analysis**

We examined the following test characteristics of VRE screening swab results for their value in predicting vancomycin resistance in sterile-site isolates of *Enterococcus*: sensitivity, specificity, negative predictive value, positive predictive value, positive likelihood ratio and negative likelihood ratio. The VRE screening results and the vancomycin sensitivity of sterile-site isolates were deemed to represent the test and response variables, respectively. A positive screening result combined with a vancomycin-resistant sterile-site isolate was deemed a true positive. A positive screening result combined with a vancomycin-sensitive sterile-site isolate was deemed a false positive. A negative screening result combined with a vancomycin-sensitive sterile-site isolate was deemed a true negative. A negative screening result combined with a vancomycin-resistant sterile-site isolate was deemed a false negative.

We calculated confidence intervals (CIs) using the Clopper–Pearson exact method, with the efficient score method used for negative predictive value in the “immediate” group (described below) and the log method used for CIs for likelihood ratios.\textsuperscript{21–23} All test characteristics were calculated using Stata 14.1 (Statcorp).

We performed subgroup analyses based on the species of *Enterococcus* isolated in culture of sterile-site specimens and the time between swab screening and sterile-site sampling. We categorized these intervals, on the basis of prior work on methicillin-resistant *S. aureus*,\textsuperscript{14} as immediate (0–48 h), recent (48 h–14 d) and remote (> 14 d).

The local prevalence of vancomycin resistance among *Enterococcus* isolates and intrinsic test characteristics for VRE swab screening both contribute to the post-test probability of vancomycin resistance in *Enterococcus* isolates. We plotted post-
test probability (y axis) as a function of prevalence (x axis, logarithmic) and denoted representative countries for which published VRE prevalence data were available. We derived prevalence data from published repositories of surveillance data on antimicrobial resistance for various countries and regions.

We generated the plot using Stata 14.1.

We calculated number needed to screen using the total number of unique patients with VRE screening swab results divided by the number of unique patients with sterile-site specimens growing Enterococcus who had prior VRE screening.

**Ethics approval**

The study was approved by the Sunnybrook Health Sciences Centre Research Ethics Board.

**Results**

**Availability of VRE screening results and prevalence of vancomycin resistance**

Culture results for sterile-site specimens were positive for Enterococcus species for a total of 619 patients. Of these, 488 (79%) had prior results for VRE screening; for 347 (71%) of these 488 patients, the sterile-site culture result was positive for *E. faecalis*, and for 141 (29%), it was positive for *E. faecium*. A total of 19 (4%) of the 488 screening results were positive for VRE, and 10 (2%) of the sterile-*Enterococcus* isolates were resistant to vancomycin. All VRE-positive sterile-site specimens grew *E. faecium* (prevalence of vancomycin-resistant *E. faecium* 7% [10/141]). Of the 131 patients who were excluded (because a prior screening result was not available), 3 had a positive culture result for VRE, and 2 of these 3 patients had a positive result on swab screening for VRE later the same day. Baseline patient characteristics are presented in Table 1.

**Utility of prior VRE screening swab results in predicting vancomycin resistance in subsequent *Enterococcus* sterile-site infections**

The utility of VRE screening for VRE in predicting vancomycin resistance in *Enterococcus* sterile-site infections is summarized in Table 2. The specificity of VRE swabs was 97% (95% CI 96%–99%), and the sensitivity was 70% (95% CI 35%–93%). The post-test probability of VRE in our study population, given a positive VRE swab screening result, was 37%, equivalent to the positive predictive value of 37% (95% CI 16%–62%); the negative predictive value was 99% (95% CI 98%–100%). The positive likelihood ratio was 28 (95% CI 14–56) and the negative likelihood ratio was 0.31 (95% CI 0.12–0.79). Most patients who undergo surveillance for VRE with swab screening do not subsequently experience an enterococcal infection; in our study population, the number needed to screen was 103 to have swab information available for 1 patient with subsequent enterococcal infection.

In a post hoc sensitivity analysis limited to patients with blood culture results for *Enterococcus* (*n* = 351), the results were similar in direction and magnitude to the overall study findings (data not shown).

**Subgroup analyses**

In the “immediate” subgroup (interval of 0–48 h between swab screening and sterile-site sampling for culture), the specificity was 99% (95% CI 93%–100%) and the sensitivity 100% (95% CI 16%–100%). In the “recent” subgroup (interval of 48 h–14 d), the specificity was 97% (95% CI 96%

---

**Table 1: Baseline characteristics of patients with sterile-site *Enterococcus* isolates who had prior swab screening for vancomycin-resistant *Enterococcus* (VRE)**

| Characteristic | No. (%) of patients* |
|---------------|----------------------|
| Age, yr, mean ± SD | 65 ± 17 |
| Sex | |
| Male | 296 (61) |
| Female | 192 (39) |
| Swab screening result for VRE | |
| Positive | 19 (4) |
| Negative | 469 (96) |
| Vancomycin resistance of sterile-site *Enterococcus* isolates | |
| Positive | 10 (2) |
| Negative | 478 (98) |
| *Enterococcus* species in sterile-site isolates | |
| *E. faecalis* | 347 (71) |
| *E. faecium* | 141 (29) |
| Admission type | |
| Medical | 214 (44) |
| Surgical | 255 (52) |
| Obstetric | 3 (1) |
| Not available | 16 (3) |
| Intensive care unit exposure | 224 (46) |
| Swab screening and collection of culture specimen performed during same admission | 374 (77) |
| Sterile site for culture | |
| Blood | 351 (72) |
| Bone | 21 (4) |
| Cerebrospinal fluid | 7 (1) |
| Dialysate | 3 (1) |
| Fluid other than cerebrospinal | 106 (22) |
| Time between swab screening and collection of culture specimen | |
| Immediate (< 48 h) | 76 (16) |
| Recent (48 h to 14 d) | 190 (39) |
| Remote (> 14 d) | 222 (45) |
| Time from swab screening to collection of culture specimen, median (IQR), d | 12 (4–31) |

*Note: IQR = interquartile range. SD = standard deviation.

*Except where noted otherwise.*
94%–99%) and the sensitivity 67% (95% CI 9%–99%). In the “remote” subgroup (interval > 14 d), the specificity was 97% (95% CI 94%–99%) and the sensitivity 60% (95% CI 15%–95%). Of note, the positive predictive value of VRE swab screening was 67% (95% CI 9%–99%) for patients in the “immediate” subgroup, and the positive likelihood ratio was 74 (95% CI 11–518).

The overall positive predictive value for \textit{E. faecium} was 64% (95% CI 31%–89%), and the positive likelihood ratio was 23 (95% CI 8.1–65). Fourteen patients had swabs taken and culture samples drawn in the “immediate” period that grew \textit{E. faecium}; in this context, the swab screening was 100% sensitive (95% CI 16%–100%) and 100% specific (95% CI 74%–100%).

**Post-test probability of vancomycin resistance**

Figure 1 shows how the local prevalence of VRE informs the post-test probability of vancomycin resistance among sterile-site \textit{Enterococcus} infections with prior VRE swab results. Specifically, small differences in prevalence lead to substantial changes in post-test probability. For example, a 15.1% prevalence of VRE in bloodstream isolates, such as that seen in a cohort of patients from North American hospitals (mostly in the United States), would translate to a post-test probability of VRE of 83% among patients with a prior positive swab result.\(^{25}\)

**Interpretation**

We explored the utility of swab screening for VRE in predicting vancomycin resistance in subsequent \textit{Enterococcus} sterile-site infections. The sensitivity of swab screening was 70%, and specificity was 97%. The positive likelihood ratio was 28, and the negative likelihood ratio was 0.31. The high specificity of VRE swab screening was preserved for each defined interval between swab screening and sterile-site sampling, whereas sensitivity diminished with increasing time. Test characteristics were optimized for \textit{E. faecium}. The results show that among patients with a prior positive result on VRE swab screening and \textit{Enterococcus} isolates identified in sterile-site cultures, VRE is sufficiently probable that empiric coverage is necessary. Similarly, a negative result on VRE swab screening may be sufficient to withhold empiric VRE coverage in settings of intermediate VRE prevalence.

This work shows the value of VRE swab screening in predicting resistance among \textit{Enterococcus} sterile-site isolates. Rolston and colleagues\(^{19}\) looked at patients with hematologic malignancies and found that VRE colonization had a positive predictive value of 29.3% (29/99) for VRE bacteremia and a negative predictive value of 99.9% (2014/2016). Kim and colleagues\(^{27}\) described a prospective study in an intensive care unit in which 9.2% (17/184) of VRE-colonized patients experienced VRE sterile-site infections. In a study of high-risk patients with febrile neutropenia, Bossaer and coworkers\(^{18}\) showed a 26.4% rate (14/53) of VRE bloodstream infection in VRE-colonized patients. Finally, Ford and colleagues\(^{17}\) found that 12.2% (10/82) of VRE-colonized patients with leukemia later experienced a VRE bloodstream infection. All of these studies involved specialized clinical settings and immunocompromised patients. More importantly, they examined the overall risk of VRE infection in VRE-swab-positive patients,\(^{16}\) whereas we examined how prior VRE swab results influence the conditional probability of vancomycin resistance once an \textit{Enterococcus} infection is documented.

Our study informs, in a novel fashion, the empiric treatment decision in the window between identification of a pathogen and availability of susceptibility results.\(^{13}\) This

| Test characteristic | Overall | Immediate (0–48 h) | Recent (48 h–14 d) | Remote (> 14 d) |
|---------------------|---------|-------------------|-------------------|----------------|
| No. of true positives | 7 | 2 | 2 | 3 |
| No. of false negatives | 466 | 73 | 182 | 211 |
| No. of false positives | 12 | 1 | 5 | 6 |
| Sensitivity, % | 70 (35–93) | 100 (16–100) | 67 (9–99) | 60 (15–95) | 70 (35–93) |
| Specificity, % | 97 (96–99) | 99 (93–100) | 97 (94–99) | 97 (94–99) | 97 (92–99) |
| Positive predictive value, % | 37 (16–62) | 67 (9–99) | 29 (3.7–57) | 33 (7.5–70) | 64 (31–89) |
| Negative predictive value, % | 99 (98–100) | 100 (95–100) | 100 (97–100) | 99 (97–100) | 98 (93–100) |
| Positive likelihood ratio | 28 (14–56) | 74 (11–518) | 25 (7.7–81) | 22 (7.5–63) | 23 (8.1–65) |
| Negative likelihood ratio | 0.31 (0.12–0.79) | 0 (0–NA) | 0.34 (0.069–1.7) | 0.41 (0.14–1.2) | 0.31 (0.12–0.80) |
| Area under ROC curve | 0.84 (0.69–0.99) | 0.99 (0.98–1.0) | 0.82 (0.49–1.0) | 0.79 (0.55–1.0) | 0.84 (0.68–0.99) |

Table 2: Test characteristics for using prior VRE swab screening results to predict vancomycin resistance among subsequent sterile-site clinical isolates of \textit{Enterococcus}.
important window has recently widened because of the availability of rapid methods for species identification. As with methicillin-resistant \textit{S. aureus}, the current findings are mechanistically consistent with the long duration of rectal colonization with VRE and with the potential to acquire VRE carriage during the hospital stay. The median duration of VRE colonization has been estimated at 4 to 9 weeks in some studies. Our results are also consistent with rectal VRE colonization being an intermediate step in the acquisition of a VRE sterile-site infection. This theoretical basis is supported by the strong correlation in genotyping of VRE isolates from matched blood cultures and rectal swabs. It makes intuitive sense that VRE colonization, the last step before VRE infection, would provide useful predictive information for a subsequent infecting isolate.

Our analysis of regional variation in the post-test probability of VRE sterile-site infection shows the influence of VRE prevalence. Local information can be used to decide whether the probability of VRE infection is sufficient to inform starting or withholding empiric therapy. Recent work has highlighted that patient survival may be directly related to appropriate early empiric coverage of VRE. Once the prevalence of vancomycin resistance in \textit{Enterococcus} sterile-site culture isolates increases beyond 1%, the post-test probability of VRE sterile-site culture isolates in a patient with a prior positive result on VRE swab screening exceeds 20%, which necessitates empiric coverage with agents such as linezolid or daptomycin. This is the most important implication of our study to clinical practice.

Moreover, when \textit{Enterococcus} sepsis is of serious concern in patients colonized with VRE — for instance, patients with hematologic malignant disease and those in critical care units — we suggest coverage for VRE immediately upon suspicion of serious infection, without waiting for species identification. Finally, when the prevalence of vancomycin resistance in \textit{Enterococcus} sterile-site culture isolates is 15% or lower, the post-test probability of VRE sterile-site culture isolates in a patient with a prior negative result on VRE swab screening is at most 5%, and consideration may be given to withholding empiric VRE coverage.

\textbf{Limitations} 

The potential limitations of this study relate to its retrospective design and the consequent potential for bias. The accuracy of test characteristics depends on culture being performed for all sterile-site infections and on the accuracy of culture and screening methods. Restriction of the study to sterile-site culture results provides confidence that positive culture results
reflect true infection. The current results were obtained for patients who met VRE screening criteria and may not be directly transferable to centres that employ universal screening. Although the study was conducted in a population with low baseline VRE prevalence, the intrinsic test characteristics should be broadly applicable. The wide CIs for some test characteristics reflect low VRE prevalence in our setting. We anticipate that future work performed at multiple centres and in areas of higher VRE prevalence will confirm the broad trends that we have described. Given the small number of positive events, the subgroup analysis by time between swab screening and sampling for culture can only be used to generate hypotheses for future work. Importantly, VRE screening swabs are already available and are employed for other purposes at many centres; the conclusions of our study can therefore be implemented with little delay. The number needed to screen to have a VRE screening swab result available for use in determining empiric therapy for an Enterococcus sterile-site isolate was 103 for our study population. Given the cost of VRE screening, we do not expect this novel clinical use, on its own, to justify broad screening of patients. Future work may show more limited cost-effectiveness for screening susceptible patients in high-risk settings.

Conclusion
Our study has shown that positive results on VRE swab screening reliably increase the probability of vancomycin resistance in Enterococcus sterile-site culture isolates, beyond usual thresholds meriting empiric coverage. New technologies have increased the time between species identification and availability of antimicrobial susceptibilities. Our results suggest that VRE should be covered during this empiric window for patients with prior positive results on VRE swab screening and a current sterile-site specimen growing Enterococcus.

References
1. Munita JM, Murray BE, Arias CA. Daptomycin for the treatment of bacteremia due to vancomycin-resistant enterococci. Int J Antimicrob Agents 2014;44:387-95.
2. Murdoch DR, Corey GR, Hoen B, et al.; International Collaboration on Endocarditis-Prospective Cohort Study (ICE-PCS) Investigators. Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. Arch Intern Med 2009;169:463-73.
3. Weinstein MP, Towns ML, Quartey SM, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis 1997;24:584-602.
4. Brook I, Frazier EH. Aerobic and anaerobic microbiology in intra-abdominal infections associated with diverticulitis. J Med Microbiol 2000;49:827-30.
5. Hidron AI, Edwards JR, Patel J, et al.; National Healthcare Safety Network Team; Participating National Healthcare Safety Network Facilities. NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006—2007. Infect Control Hosp Epidemiol 2008;29:996-1011.
6. Barber KE, King ST, Sover KR, et al. Therapeutic options for vancomycin-resistant enterococcal bacteremia. Expert Rev Anti Infect Ther 2013;11:1363-77.
7. Papadimitriou-Olivgeris M, Drougka E, Fligou F, et al. Risk factors for enterococcal infection and colonization by vancomycin-resistant enterococci in critically ill patients. Infect Control Hosp Epidemiol 2014;35:1013-22.
8. Sohn KM, Peck KR, Joo EJ, et al. Duration of colonization and risk factors for prolonged carriage of vancomycin-resistant enterococci after discharge from the hospital. Int J Infect Dis 2013;17:e240-6.
9. Yoon YK, Kim HJ, Lee WJ, et al. Clinical predictive rule for identifying patients with vancomycin-resistant enterococci (VRE) at the time of admission to the intensive care unit in a low VRE prevalence setting. J Antimicrob Chemother 2014;69:2963-9.
10. DazGranados CA, Zimmer SM, Klein M, et al. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005;41:327-33.
11. Gantert KE, Polkinghorn KR, Kotsanas D, et al. Vancomycin-resistant enterococci colonization does not increase mortality in end-stage kidney failure: a case-control study. J Hosp Infect 2013;85:289-96.
12. Zasowski EJ, Claeyx KC, Lagrij AF, et al. Time is of the essence: the impact of delayed antibiotic therapy on patient outcomes in hospital-onset enterococcal bloodstream infections. Clin Infect Dis 2016;62:1242-50.
13. MacFadden DR, Leis JA, Muhareka S, et al. The opening and closing of empiric windows: the impact of rapid microbiologic diagnostics. Clin Infect Dis 2015;60:1199-200.
14. MacFadden DR, Elligsen M, Robiecak A, et al. Utility of prior screening for methicillin-resistant Staphylococcus aureus in predicting resistance of S. aureus infections. CMAJ 2013;185:E72-30.
15. Karcher NM, Skidmore KS, Flood PC, et al. Risk of vancomycin-resistant enterococci bloodstream infection among patients colonized with vancomycin-resistant enterococci. Braz J Infect Dis 2015;19:58-61.
16. Salgado CD. The risk of developing a vancomycin-resistant Enterococcus blood stream infection following healthcare exposure. Clin Infect Dis 2015;60:1647-50.
17. Bossaer JB, Hall PD, Garrett-Mayer E. Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. Support Care Cancer 2010;18:231-7.
18. Rolston KV, Jiang Y, Matar M. VRE fecal colonization/infection in cancer patients. Bone Marrow Transplant 2007;39:567-8.
19. Elligsen M, Walker SA, Simor A, et al. Prospective audit and feedback of antimicrobial stewardship in critical care: program implementation, experience, and challenges. Can J Hosp Pharm 2012;65:31-6.
20. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998;17:857-72.
21. Simel DL, Samsa GP, Matchar DB. Likelihood ratios with confidence: sample size estimation for diagnostic test studies. J Clin Epidemiol 1991;44:763-70.
22. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26:403-4.
23. Zhan G, DeCorby M, Lang N, et al. Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005—2006. Antimicrob Agents Chemother 2008;52:1430-7.
24. Biedenbach DJ, Moet GJ, Jones RN. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997—2002). Diagn Microbiol Infect Dis 2004;50:59-69.
25. Central Asia and Eastern European surveillance of antimicrobial resistance: annual report 2014. Copenhagen (Denmark): WHO Regional Office for Europe; 2015. Available: www.euro.who.int/en/health-topics/disease-prevention/antimicrobial-resistant
durgessurveillance/publications/2015/central-asian-and-eastern-european-surveillance-of-antimicrobial-resistance—annual-report-2014 (accessed 2016 Dec. 17).
26. Clopper CJ, Pearson ES. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934;26:403-4.
27. Kim YJ, Kim SI, Kim YR, et al. Risk factors for prolonged carriage of vancomycin-resistant enterococci in patients discharged from hospitals: a 12-year retrospective cohort study. J Clin Microbiol 2013;51:3374-9.
28. Young YK, Lee SE, Lee J, et al. Risk factors for prolonged carriage of vancomycin-resistant Enterococcus faecium among patients in intensive care units: a case-control study. J Antimicrob Chemother 2014;69:1581-8.
29. Vazquez-Guillamet C, Kollef MH. Treatment of Gram-positive infections in critically ill patients. BMC Infect Dis 2014;14:92.

Affiliations: Department of Medicine (Brasg), Division of Infectious Diseases (MacFadden, Dannan) and Division of Clinical Epidemiology (Dannan), University of Toronto; Department of Pharmacy (Elligsen), Sunnybrook Health Sciences Centre, Toronto, Ont.

Contributors: All of the authors contributed to development of the study concept and design, conduct of the analyses and interpretation of the results. All of the authors participated in drafting the manuscript and revising it for important intellectual content, gave final approval of the version to be published and agreed to be accountable for all aspects of the work.

Supplemental information: For reviewer comments and the original submission of this manuscript, please see www.cmajopen.ca/content/5/3/E632/suppl/DC1.